Open access · US-GOV via ClinicalTrials.gov Clinical trial

Assessing the Role of GLP-1 Receptor Agonist Semaglutide and Dual GLP-I/GIP Receptor Agonist Tirzepatide in Delaying Genetic Aging in Adult Obese Patients Using the iWatchAge Technology

Authors not listed

Second Affiliated Hospital, Zhejiang University, School of Medicine · 2025

Epigenetic alterations Chronic inflammation Metformin Human Randomized controlled trial

Abstract

This study is a prospective, randomized, open-label clinical trial enrolling 66 adults with simple obesity who have not used weight-loss medications for at least 3 months. Participants will receive semaglutide, tirzepatide, or metformin for 24 weeks. Changes in "biological (epigenetic) age" will be assessed using the iWatchAge DNA methylation age test, while simultaneously monitoring improvements in aging-related biomarkers such as inflammatory factors, metabolic parameters, and body composition. The aim is to determine whether incretin-based therapies can reverse or slow obesity-related accelerated epigenetic aging and to provide new clinical evidence for interventions targeting obesity and aging.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-10-22 MST

Cite this

APA

Anonymous. (2025). Assessing the Role of GLP-1 Receptor Agonist Semaglutide and Dual GLP-I/GIP Receptor Agonist Tirzepatide in Delaying Genetic Aging in Adult Obese Patients Using the iWatchAge Technology. <em>Second Affiliated Hospital, Zhejiang University, School of Medicine</em>. https://clinicaltrials.gov/study/NCT07293325

Vancouver

Anonymous. Assessing the Role of GLP-1 Receptor Agonist Semaglutide and Dual GLP-I/GIP Receptor Agonist Tirzepatide in Delaying Genetic Aging in Adult Obese Patients Using the iWatchAge Technology. Second Affiliated Hospital, Zhejiang University, School of Medicine. 2025.

BibTeX

@misc{anon2025Assess, title = {Assessing the Role of GLP-1 Receptor Agonist Semaglutide and Dual GLP-I/GIP Receptor Agonist Tirzepatide in Delaying Genetic Aging in Adult Obese Patients Using the iWatchAge Technology}, author = {Anonymous}, journal = {Second Affiliated Hospital, Zhejiang University, School of Medicine}, year = {2025}, }